Implementing Genome-Driven Oncology

Cell

Volumn 168, Issue 4, 2017, Pages 584-599

  Hyman, David M ^a,b   Taylor, Barry S ^a   Baselga, José ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

basket studies; genome driven oncology; next generation sequencing; Precision medicine; targeted therapy

Indexed keywords

DNA; EVEROLIMUS; IMATINIB; NERATINIB; OLAPARIB; TUMOR MARKER; VEMURAFENIB;

BLADDER CANCER; BREAST CANCER; CANCER OF UNKNOWN PRIMARY SITE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DERMATOFIBROSARCOMA PROTUBERANS; DNA SEQUENCE; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENOME; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HISTIOCYTOSIS; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; MYELODYSPLASTIC SYNDROME; NEOPLASM; NEXT GENERATION SEQUENCING; ONCOLOGY; OVARY CANCER; PANCREAS CANCER; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOFT TISSUE SARCOMA; STOMACH CANCER; THYROID CANCER; TUMOR GENE; UTERINE CERVIX CANCER; ANIMAL; DRUG RESISTANCE; GENETIC HETEROGENEITY; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; MISSENSE MUTATION; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ANIMALS; DRUG RESISTANCE, NEOPLASM; GENETIC HETEROGENEITY; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION, MISSENSE; NEOPLASMS; PRECISION MEDICINE; SEQUENCE ANALYSIS, DNA;

EID: 85012024906     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2016.12.015     Document Type: Review

References (97)

1. Baselga, J., Campone, M., Piccart, M., Burris, H.A. 3rd, Rugo, H.S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K.I., Lebrun, F., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366 (2012), 520–529.
2. Beltran, H., Eng, K., Mosquera, J.M., Sigaras, A., Romanel, A., Rennert, H., Kossai, M., Pauli, C., Faltas, B., Fontugne, J., et al. Whole-exome sequencing of metastatic cancer and biomarkers of treatment response. JAMA Oncol. 1 (2015), 466–474.
3. Bitler, B.G., Aird, K.M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A.V., Schultz, D.C., Liu, Q., Shih, IeM., Conejo-Garcia, J.R., et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat. Med. 21 (2015), 231–238.
4. Bleeker, F.E., Felicioni, L., Buttitta, F., Lamba, S., Cardone, L., Rodolfo, M., Scarpa, A., Leenstra, S., Frattini, M., Barbareschi, M., et al. AKT1(E17K) in human solid tumours. Oncogene 27 (2008), 5648–5650.
5. Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P.N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467 (2010), 596–599.
6. Bose, R., Kavuri, S.M., Searleman, A.C., Shen, W., Shen, D., Koboldt, D.C., Monsey, J., Goel, N., Aronson, A.B., Li, S., et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 3 (2013), 224–237.
7. Bower, H., Björkholm, M., Dickman, P.W., Höglund, M., Lambert, P.C., Andersson, T.M., Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J. Clin. Oncol. 34 (2016), 2851–2857.
8. Brenan, L., Andreev, A., Cohen, O., Pantel, S., Kamburov, A., Cacchiarelli, D., Persky, N.S., Zhu, C., Bagul, M., Goetz, E.M., et al. Phenotypic characterization of a comprehensive set of MAPK1/ERK2 missense mutants. Cell Rep. 17 (2016), 1171–1183.
9. Brose, M.S., Cabanillas, M.E., Cohen, E.E., Wirth, L.J., Riehl, T., Yue, H., Sherman, S.I., Sherman, E.J., Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 17 (2016), 1272–1282.
10. Cardoso, F., van't Veer, L.J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., Pierga, J.Y., Brain, E., Causeret, S., DeLorenzi, M., et al., MINDACT Investigators. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N. Engl. J. Med. 375 (2016), 717–729.
11. Carpten, J.D., Faber, A.L., Horn, C., Donoho, G.P., Briggs, S.L., Robbins, C.M., Hostetter, G., Boguslawski, S., Moses, T.Y., Savage, S., et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448 (2007), 439–444.
12. Carter, S.L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P.W., Onofrio, R.C., Winckler, W., Weir, B.A., et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30 (2012), 413–421.
13. Chang, M.T., Asthana, S., Gao, S.P., Lee, B.H., Chapman, J.S., Kandoth, C., Gao, J., Socci, N.D., Solit, D.B., Olshen, A.B., et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat. Biotechnol. 34 (2016), 155–163.
14. Chen, C.D., Welsbie, D.S., Tran, C., Baek, S.H., Chen, R., Vessella, R., Rosenfeld, M.G., Sawyers, C.L., Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10 (2004), 33–39.
15. Cheng, D.T., Mitchell, T.N., Zehir, A., Shah, R.H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z.Y., Won, H.H., Scott, S.N., et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17 (2015), 251–264.
16. Cortes, J.E., Kantarjian, H., Shah, N.P., Bixby, D., Mauro, M.J., Flinn, I., O'Hare, T., Hu, S., Narasimhan, N.I., Rivera, V.M., et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 367 (2012), 2075–2088.
17. Cunanan, K.M., Gonen, M., Shen, R., Hyman, D.M., Riely, G.J., Begg, C.B., Iasonos, A., Basket trials in oncology: a trade-off between complexity and efficiency. J. Clin. Oncol. 35 (2016), 271–273.
18. Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002), 949–954.
19. Dawson, S.J., Tsui, D.W., Murtaza, M., Biggs, H., Rueda, O.M., Chin, S.F., Dunning, M.J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368 (2013), 1199–1209.
20. De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K.T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11 (2010), 753–762.
21. Diaz, L.A. Jr., Williams, R.T., Wu, J., Kinde, I., Hecht, J.R., Berlin, J., Allen, B., Bozic, I., Reiter, J.G., Nowak, M.A., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486 (2012), 537–540.
22. Drilon, A., Rekhtman, N., Arcila, M., Wang, L., Ni, A., Albano, M., Van Voorthuysen, M., Somwar, R., Smith, R.S., Montecalvo, J., et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 17 (2016), 1653–1660.
23. Druker, B.J., Guilhot, F., O'Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M.W., Silver, R.T., Goldman, J.M., Stone, R.M., et al., IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355 (2006), 2408–2417.
24. Eubank, M.H., Hyman, D.M., Kanakamedala, A.D., Gardos, S.M., Wills, J.M., Stetson, P.D., Automated eligibility screening and monitoring for genotype-driven precision oncology trials. J. Am. Med. Inform. Assoc. 23 (2016), 777–781.
25. Frampton, G.M., Fichtenholtz, A., Otto, G.A., Wang, K., Downing, S.R., He, J., Schnall-Levin, M., White, J., Sanford, E.M., An, P., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 31 (2013), 1023–1031.
26. Frampton, G.M., Ali, S.M., Rosenzweig, M., Chmielecki, J., Lu, X., Bauer, T.M., Akimov, M., Bufill, J.A., Lee, C., Jentz, D., et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 5 (2015), 850–859.
27. Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366 (2012), 883–892.
28. Grossman, R.L., Heath, A.P., Ferretti, V., Varmus, H.E., Lowy, D.R., Kibbe, W.A., Staudt, L.M., Toward a shared vision for cancer genomic data. N. Engl. J. Med. 375 (2016), 1109–1112.
29. Halevy, O., Michalovitz, D., Oren, M., Different tumor-derived p53 mutants exhibit distinct biological activities. Science 250 (1990), 113–116.
30. Hata, A.N., Niederst, M.J., Archibald, H.L., Gomez-Caraballo, M., Siddiqui, F.M., Mulvey, H.E., Maruvka, Y.E., Ji, F., Bhang, H.E., Krishnamurthy Radhakrishna, V., et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22 (2016), 262–269.
31. He, J., Abdel-Wahab, O., Nahas, M.K., Wang, K., Rampal, R.K., Intlekofer, A.M., Patel, J., Krivstov, A., Frampton, G.M., Young, L.E., et al. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood 127 (2016), 3004–3014.
32. Hoadley, K.A., Yau, C., Wolf, D.M., Cherniack, A.D., Tamborero, D., Ng, S., Leiserson, M.D., Niu, B., McLellan, M.D., Uzunangelov, V., et al., Cancer Genome Atlas Research Network. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158 (2014), 929–944.
33. Hoshino, A., Costa-Silva, B., Shen, T.L., Rodrigues, G., Hashimoto, A., Tesic Mark, M., Molina, H., Kohsaka, S., Di Giannatale, A., Ceder, S., et al. Tumour exosome integrins determine organotropic metastasis. Nature 527 (2015), 329–335.
34. Hyman, D.M., Puzanov, I., Subbiah, V., Faris, J.E., Chau, I., Blay, J.Y., Wolf, J., Raje, N.S., Diamond, E.L., Hollebecque, A., et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N. Engl. J. Med. 373 (2015), 726–736.
35. Hyman, D.M., Smyth, L., Bedard, P.L., Oza, A., Dean, E., Armstrong, A., Lima, J., Bando, H., Kabos, P., Perez-Fidalgo, J.A., et al. AZD5363, a catalytic pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solid tumors. Mol. Cancer Ther., 14, 2015 Abstract B109.
36. Hyman, D.M., Solit, D.B., Arcila, M.E., Cheng, D.T., Sabbatini, P., Baselga, J., Berger, M.F., Ladanyi, M., Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discov. Today 20 (2015), 1422–1428.
37. Hyman, D.M., Piha-Paul, S., Rodon, J., Saura, C., Puzanov, I., Shapiro, G., Loi, S., Joensuu, H., Hanrahan, A., Modi, S., et al. Neratinib for ERBB2 mutant, HER2 non-amplified, metastatic breast cancer: Preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial. Cancer Res., 76, 2016 Abstract PD5–05.
38. Jänne, P.A., Yang, J.C., Kim, D.W., Planchard, D., Ohe, Y., Ramalingam, S.S., Ahn, M.J., Kim, S.W., Su, W.C., Horn, L., et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 1689–1699.
39. Juric, D., Castel, P., Griffith, M., Griffith, O.L., Won, H.H., Ellis, H., Ebbesen, S.H., Ainscough, B.J., Ramu, A., Iyer, G., et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature 518 (2015), 240–244.
40. Kandoth, C., McLellan, M.D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J.F., Wyczalkowski, M.A., et al. Mutational landscape and significance across 12 major cancer types. Nature 502 (2013), 333–339.
41. Karnoub, A.E., Weinberg, R.A., Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 9 (2008), 517–531.
42. Kaufman, B., Shapira-Frommer, R., Schmutzler, R.K., Audeh, M.W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S.M., Hubert, A., et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 33 (2015), 244–250.
43. Kim, E., Ilic, N., Shrestha, Y., Zou, L., Kamburov, A., Zhu, C., Yang, X., Lubonja, R., Tran, N., Nguyen, C., et al. Systematic functional interrogation of rare cancer variants identifies oncogenic alleles. Cancer Discov. 6 (2016), 714–726.
44. Kim, K.H., Kim, W., Howard, T.P., Vazquez, F., Tsherniak, A., Wu, J.N., Wang, W., Haswell, J.R., Walensky, L.D., Hahn, W.C., et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat. Med. 21 (2015), 1491–1496.
45. Kitzman, J.O., Starita, L.M., Lo, R.S., Fields, S., Shendure, J., Massively parallel single-amino-acid mutagenesis. Nat. Methods 12 (2015), 203–206 4, 206.
46. Kivioja, T., Vähärautio, A., Karlsson, K., Bonke, M., Enge, M., Linnarsson, S., Taipale, J., Counting absolute numbers of molecules using unique molecular identifiers. Nat. Methods 9 (2011), 72–74.
47. LaFave, L.M., Béguelin, W., Koche, R., Teater, M., Spitzer, B., Chramiec, A., Papalexi, E., Keller, M.D., Hricik, T., Konstantinoff, K., et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat. Med. 21 (2015), 1344–1349.
48. Lai, A., Kahraman, M., Govek, S., Nagasawa, J., Bonnefous, C., Julien, J., Douglas, K., Sensintaffar, J., Lu, N., Lee, K.J., et al. Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts. J. Med. Chem. 58 (2015), 4888–4904.
49. Landrum, M.J., Lee, J.M., Benson, M., Brown, G., Chao, C., Chitipiralla, S., Gu, B., Hart, J., Hoffman, D., Hoover, J., et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 44:D1 (2016), D862–D868.
50. Lanman, R.B., Mortimer, S.A., Zill, O.A., Sebisanovic, D., Lopez, R., Blau, S., Collisson, E.A., Divers, S.G., Hoon, D.S., Kopetz, E.S., et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS ONE, 10, 2015, e0140712.
51. Lawrence, M.S., Stojanov, P., Mermel, C.H., Robinson, J.T., Garraway, L.A., Golub, T.R., Meyerson, M., Gabriel, S.B., Lander, E.S., Getz, G., Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505 (2014), 495–501.
52. Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., Skora, A.D., Luber, B.S., Azad, N.S., Laheru, D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372 (2015), 2509–2520.
53. Le Tourneau, C., Paoletti, X., Servant, N., Bièche, I., Gentien, D., Rio Frio, T., Vincent-Salomon, A., Servois, V., Romejon, J., Mariani, O., et al. Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. Br. J. Cancer 111 (2014), 17–24.
54. Loxo (2016). Press release: Loxo Oncology receives breakthrough therapy designation from U.S. Food and Drug Administration for LOXO-101. https://ir.loxooncology.com/press-releases/loxo-oncology-receives-breakthrough-therapy-designation-from-u.s.-food-and-drug-administration-for-loxo-101.
55. Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373 (2015), 1697–1708.
56. Melnikov, A., Rogov, P., Wang, L., Gnirke, A., Mikkelsen, T.S., Comprehensive mutational scanning of a kinase in vivo reveals substrate-dependent fitness landscapes. Nucleic Acids Res., 42, 2014, e112.
57. Melo, S.A., Luecke, L.B., Kahlert, C., Fernandez, A.F., Gammon, S.T., Kaye, J., LeBleu, V.S., Mittendorf, E.A., Weitz, J., Rahbari, N., et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523 (2015), 177–182.
58. Meric-Bernstam, F., Brusco, L., Shaw, K., Horombe, C., Kopetz, S., Davies, M.A., Routbort, M., Piha-Paul, S.A., Janku, F., Ueno, N., et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J. Clin. Oncol. 33 (2015), 2753–2762.
59. Milojkovic, D., Apperley, J., Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin. Cancer Res. 15 (2009), 7519–7527.
60. Mirza, M.R., Monk, B.J., Herrstedt, J., Oza, A.M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J.A., Lorusso, D., Vergote, I., et al., ENGOT-OV16/NOVA Investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med. 375 (2016), 2154–2164.
61. Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486 (2012), 532–536.
62. Pearson, A., Smyth, E., Babina, I.S., Herrera-Abreu, M.T., Tarazona, N., Peckitt, C., Kilgour, E., Smith, N.R., Geh, C., Rooney, C., et al. High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial. Cancer Discov. 6 (2016), 838–851.
63. Peschard, P., Fournier, T.M., Lamorte, L., Naujokas, M.A., Band, H., Langdon, W.Y., Park, M., Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell 8 (2001), 995–1004.
64. Piccart-Gebhart, M.J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al., Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353 (2005), 1659–1672.
65. Planchard, D., Kim, T.M., Mazieres, J., Quoix, E., Riely, G., Barlesi, F., Souquet, P.J., Smit, E.F., Groen, H.J., Kelly, R.J., et al. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol. 17 (2016), 642–650.
66. Poulikakos, P.I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M.T., et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480 (2011), 387–390.
67. Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R.L., Bardelli, A., Bernards, R., Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483 (2012), 100–103.
68. Pritchard, C.C., Mateo, J., Walsh, M.F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N. Engl. J. Med. 375 (2016), 443–453.
69. Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372 (2015), 30–39.
70. Roychowdhury, S., Iyer, M.K., Robinson, D.R., Lonigro, R.J., Wu, Y.M., Cao, X., Kalyana-Sundaram, S., Sam, L., Balbin, O.A., Quist, M.J., et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci. Transl. Med., 3, 2011, 111ra121.
71. Russo, M., Siravegna, G., Blaszkowsky, L.S., Corti, G., Crisafulli, G., Ahronian, L.G., Mussolin, B., Kwak, E.L., Buscarino, M., Lazzari, L., et al. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov. 6 (2016), 147–153.
72. Saglio, G., Kim, D.W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R.E., Hochhaus, A., Hughes, T.P., et al., ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 362 (2010), 2251–2259.
73. Scher, H.I., Fizazi, K., Saad, F., Taplin, M.E., Sternberg, C.N., Miller, K., de Wit, R., Mulders, P., Chi, K.N., Shore, N.D., et al., AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367 (2012), 1187–1197.
74. Schrader, K.A., Cheng, D.T., Joseph, V., Prasad, M., Walsh, M., Zehir, A., Ni, A., Thomas, T., Benayed, R., Ashraf, A., et al. Germline variants in targeted tumor sequencing using matched normal DNA. JAMA Oncol. 2 (2016), 104–111.
75. Shaw, A.T., Kim, D.W., Mehra, R., Tan, D.S., Felip, E., Chow, L.Q., Camidge, D.R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 370 (2014), 1189–1197.
76. Shaw, A.T., Friboulet, L., Leshchiner, I., Gainor, J.F., Bergqvist, S., Brooun, A., Burke, B.J., Deng, Y.L., Liu, W., Dardaei, L., et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N. Engl. J. Med. 374 (2016), 54–61.
77. Shen, R., Seshan, V.E., FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res., 44, 2016, e131.
78. Siu, L.L., Lawler, M., Haussler, D., Knoppers, B.M., Lewin, J., Vis, D.J., Liao, R.G., Andre, F., Banks, I., Barrett, J.C., et al. Facilitating a culture of responsible and effective sharing of cancer genome data. Nat. Med. 22 (2016), 464–471.
79. Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344 (2001), 783–792.
80. Stransky, N., Cerami, E., Schalm, S., Kim, J.L., Lengauer, C., The landscape of kinase fusions in cancer. Nat. Commun., 5, 2014, 4846.
81. Swain, S.M., Baselga, J., Kim, S.B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.M., Schneeweiss, A., Heeson, S., et al., CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N. Engl. J. Med. 372 (2015), 724–734.
82. Tabernero, J., Bahleda, R., Dienstmann, R., Infante, J.R., Mita, A., Italiano, A., Calvo, E., Moreno, V., Adamo, B., Gazzah, A., et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 33 (2015), 3401–3408.
83. Tannock, I.F., Hickman, J.A., Limits to personalized cancer medicine. N. Engl. J. Med. 375 (2016), 1289–1294.
84. Telli, M.L., Timms, K.M., Reid, J., Hennessy, B., Mills, G.B., Jensen, K.C., Szallasi, Z., Barry, W.T., Winer, E.P., Tung, N.M., et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin. Cancer Res. 22 (2016), 3764–3773.
85. Thress, K.S., Paweletz, C.P., Felip, E., Cho, B.C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21 (2015), 560–562.
86. Tiacci, E., Park, J.H., De Carolis, L., Chung, S.S., Broccoli, A., Scott, S., Zaja, F., Devlin, S., Pulsoni, A., Chung, Y.R., et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N. Engl. J. Med. 373 (2015), 1733–1747.
87. Tirosh, I., Izar, B., Prakadan, S.M., Wadsworth, M.H. 2nd, Treacy, D., Trombetta, J.J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352 (2016), 189–196.
88. Toy, W., Shen, Y., Won, H., Green, B., Sakr, R.A., Will, M., Li, Z., Gala, K., Fanning, S., King, T.A., et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 45 (2013), 1439–1445.
89. Turner, N.C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al., PALOMA3 Study Group. Palbociclib in hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 373 (2015), 209–219.
90. Vaishnavi, A., Le, A.T., Doebele, R.C., TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 5 (2015), 25–34.
91. Voest, E.E., Bernards, R., DNA-guided precision medicine for cancer: a case of irrational exuberance?. Cancer Discov. 6 (2016), 130–132.
92. Wan, P.T., Garnett, M.J., Roe, S.M., Lee, S., Niculescu-Duvaz, D., Good, V.M., Jones, C.M., Marshall, C.J., Springer, C.J., Barford, D., Marais, R., Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 (2004), 855–867.
93. Yang, J.C., Sequist, L.V., Geater, S.L., Tsai, C.M., Mok, T.S., Schuler, M., Yamamoto, N., Yu, C.J., Ou, S.H., Zhou, C., et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 16 (2015), 830–838.
94. Yao, Z., Torres, N.M., Tao, A., Gao, Y., Luo, L., Li, Q., de Stanchina, E., Abdel-Wahab, O., Solit, D.B., Poulikakos, P.I., Rosen, N., BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition. Cancer Cell 28 (2015), 370–383.
95. Yu, M., Bardia, A., Wittner, B.S., Stott, S.L., Smas, M.E., Ting, D.T., Isakoff, S.J., Ciciliano, J.C., Wells, M.N., Shah, A.M., et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339 (2013), 580–584.
96. Zaretsky, J.M., Garcia-Diaz, A., Shin, D.S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D.Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375 (2016), 819–829.
97. Zhang, J., Walsh, M.F., Wu, G., Edmonson, M.N., Gruber, T.A., Easton, J., Hedges, D., Ma, X., Zhou, X., Yergeau, D.A., et al. Germline mutations in predisposition genes in pediatric cancer. N. Engl. J. Med. 373 (2015), 2336–2346.